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Abstract
Background: Alzheimer disease (AD) is a progressive neurodegenerative disease that destroys memory and
cognitive skills. AD is characterized by the presence of two types of neuropathological hallmarks: extracellular plaques
consisting of amyloid β-peptides and intracellular neurofibrillary tangles of hyperphosphorylated tau proteins. The
disease affects 5 million people in the United States and 44 million world-wide. Currently there is no drug that can
cure, stop or even slow the progression of the disease. If no cure is found, by 2050 the number of alzheimer’s patients
in the U.S. will reach 15 million and the cost of caring for them will exceed $ 1 trillion annually.
Results: The present paper develops a mathematical model of AD that includes neurons, astrocytes, microglias and
peripheral macrophages, as well as amyloid β aggregation and hyperphosphorylated tau proteins. The model is
represented by a system of partial differential equations. The model is used to simulate the effect of drugs that either
failed in clinical trials, or are currently in clinical trials.
Conclusions: Based on these simulations it is suggested that combined therapy with TNF-α inhibitor and anti
amyloid β could yield significant efficacy in slowing the progression of AD.
Keywords: Alzheimer disease, Mathematical modeling, Drug treatment
Background
AD is the most common form of dementia. The disease
is an irreversible, progressive, brain disorder that destroys
memory and cognitive skills, and eventually the ability to
carry out even the simplest tasks. While the genetic inher-
itability of AD is in the range of 50 –80% [1, 2], the cause
of the disease is mostly unknown. The disease strikes age-
ing people typically 65 or older, and twice more women
than men. In 2015 there were more than 5 million people
in the United States with AD, and 44 millions world-wide
[3]. The cost of caring for AD patients in the U.S. was
estimated at $226 billions for 2015 [3].
AD is characterized by the presence of two types of
neuropathological hallmarks: extracellular plaques and
intracellular neurofibrillary tangles (NFTs). The extracel-
lular plaques consist primarily of amyloid β-peptide (Aβ)
deposits. The NFTs are intraneural aggregation of hyper-
phosphorylated tau proteins. Reactive oxygen species
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(ROS) appears to be one of the early events in the pro-
gression of the disease [4]. Amyloid precursor protein
(APP) on neurons membrane constitutively shed Aβ pep-
tides [5]. High levels of ROS promote abnormal deposition
of Aβ [4, 6]. Tau protein in the central nervous system
(CNS) is predominantly expressed in neurons; its main
role is to promote microtubles assembly and stability.
Glycogen synthase kinase-type 3(GSK-3) is activated by
the abnormally produced Aβ , and it mediates the hyper-
phosphorylation of tau proteins [4, 6–9].
The hyperphosphorylated tau proteins cause microtu-
ble depolymerization and destruction, as they aggregate
to form neurofibrillary tangles. This results in neuronal
death and release of the NFTs to the extracellular environ-
ment [4, 10].
The non-neuronal cells in the brain consist of cells that
support neurons directly, mostly astrocytes, and immune
cells.
Microglias are the resident macrophages in the brain.
They constitute the main active immune cells in the brain.
They are activated by soluble Aβ oligomers which build
up from the Aβ deposits [11, 12].
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Astrocytes are in close proximity to neurons. They sup-
port neuronal cross-talk, and mediate the transport of
nutrients from the blood to neurons. Astrocytes are acti-
vated primarily by TNF-α, but also by Aβ [10, 13–16].
Activated astrocytes produce Aβ , but at a smaller rate
than neurons [16]. Activated astrocytes also produce
MCP-1, which attracts monocytes from the blood into
the plaques [17–19]. The monocytes differentiate into
proinflammatory macrophages, Mˆ1, but may then change
phenotype into anti-inflammatory Mˆ2 macrophage. Acti-
vated microglias have two phenotypes: proinflamma-
tory M1 macroglia and anti-inflammatory M2 macroglia
[12, 20]. Macrophages have a major role in Aβ clearance
[12, 20], but activated microglia are poorly phagocytic for
Aβ compared to peripheral macrophages [21].M1 and Mˆ1
macrophages are neurotoxic; they produce proinflamma-
tory cytokines TNF-α, IL-6, IL-12 and IL-1β [20, 22, 23].
M2 microglias and peripheral Mˆ2 macrophages produce
anti-inflammatory cytokines IL-10, IL-13, IL-4 and TGF-
β [20]. The neuronal stress caused by the proinflamma-
tory cytokines, is resisted by IL-10, IL-13 and IL-4, but
nevertheless it contributes to neuronal damage and death
[20, 22, 23].
There are currently no drugs that can cure AD, or stop
its progression. Many clinical trials of drugs aimed at pre-
venting or clearing the Aβ and tau pathology have failed
to demonstrate efficacy [24–27]. Currently the only treat-
ment of AD is by medications that are used to treat the
symptoms of the disease.
The role of TGF-β is somewhat controversial [28]. On
one hand, TGF-β provides protection against neuronin-
flammation and neurondegeneration [29–34], but on the
other hand, TGF-β-induced TIAF1 interacts with amy-
loid fibrils to favorably support plaque formation [28],
and blocking TGF-β-smad2/3 in peripheral macrophages
mitigates AD pathology [35].
Figure 1 is a schematics of the network associated with
the progression of AD. Figure 1a shows the network
within a neuron which leads from ROS to NFTs and the
destruction of microtubules. Figure 1b shows the network
of activated cells, microglia, astrocyte and monocyte-
derived macrophages and their effect on neurons and
their microenvironment.
In this paper we develop a mathematical model of AD.
Themodel is represented by a system of partial differential
equations (PDEs) based on Fig. 1. For simplicity we repre-
sent all the proinflammatory cytokines by TNF-α, and all
the anti-inflammatory cytokines by IL-10.
We shall use our model to conduct in silico tri-
als with several drugs: TNF-α inhibitor, anti-Aβ drug,
MCP-1 inhibitor, and injection of TGF-β . Simulations of
the model show that continuous treatment with TNF-α
inhibitor yields a slight decrease the death of neurons, and
anti-Aβ drug yields a slight decrease in the aggregation of
Aβ over 10 years period, while the benefits from injection
of TGF-β and MCP-1 inhibitor drugs are negligible. This
suggests that clinical trials consider combination therapy
with TNF-α and anti-Aβ drugs.
We note that Fig. 1 does not display neurites: the pro-
jections of axons and dendrites from the body of neurons.
It is known that the aggregations of Aβ mediate rapid
disruption of synaptic plasticity and memory [36–39].
Thus the progression of AD in terms of reduction in den-
dritic complexity and synaptic dysfunction will not be
considered in the present paper.
We conclude the Introduction by mentioning earlier
mathematical models which deal with some aspects of
AD: Aβ polymerization [40], Aβ plaque formation and the
role of prions interacting with Aβ [41, 42], linear cross-
talk among brain cells and Aβ [43], and the influence of




The mathematical model is based on Fig. 1 and is repre-
sented by a system of partial differential equations. Table 1
lists the variables used in the model.
Equations for A β
The amyloid-β within neurons, Aiβ , are constitutively
released from APP at a rate λiβ and are degraded at a
rate dAiβ . Under reactive oxidative stress, R, A
i
β is overpro-

















whereN0 is the reference density of the neuron cells in the
brain.
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where K¯Aoβ is a Michaelis-Menten coefficient. Neurons die
at a rate ∂N




∣∣ to the growth rate of Aoβ , which is the first
term on the right-hand side of Eq. (2). The second term on
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Fig. 1 Schematic network in AD: a Amyloid precurser protein (APP) sheds Amyloid β peptides. ROS promotes abnormal production of Aβ [5, 6],
which activates GSK-3 [4, 6, 8]. Activated GSK-3 mediates hyperphosphrylation of tau proteins [4, 6], which results in the formation of NFTs [10] and
destruction of microtubules [4, 10], leading to neuron death. b Astrocytes are activated by Aoβ [10, 16] and TNF-α [14, 15], and they produce MCP-1
[17–19], which attracts macrophages into the tissue [17, 19]. NFT activates microglias [10, 13, 15]. Activated proinflammatory microglias and
microphages produce TNF-α and other proinflammatory cytokines [20, 22, 23], while anti-inflammatory microglias and macrophages produce IL-10
and other anti-inflammatory cytokines [20, 22, 23]. Dead neurons release Aβ and NFTs, and soluble Aβ oligomers activate microglia [11, 12].
Activated astrocytes secrete Aβ [16]. Aβ deposit is reduced through endocytosis by microglia and macrophages [12, 20]
the right-hand side of Eq. (2) represents Aβ constitutively
released from APP [5], and the third term accounts for Aβ
released by activated astrocytes [16]; A0 is the reference
density of the astrocyte cells in the brain.A0β is cleared pri-
marily by peripheral macrophages Mˆ1 and Mˆ2, but also by
activated microglias M1 and M2, so dAoβMˆ > dAoβM [21],
and Mˆ1 M1 are more effective in clearing Aoβ than Mˆ2 and
M2 [46, 47] so 0 ≤ θ < 1. APP on live neurons shed
Aβ peptides both inside the neurons (as Aiβ ) and outside
the neurons (as Aoβ ). We assume that most Aoβ are pro-
duced from dead neurons. Hence, in Eq. (2), we neglected
the production of Aoβ by live neurons. We also assumed
that ROS increases primarily the Aβ that are within live
neurons, and thus neglected the increase of Aoβ by ROS.
Equation for τ
Tau protein is constitutively produced at some rate
λτ0. We assume that when Aiβ production exceeds a
threshold Ai0β , GSK-3 becomes activated and it mediates
Hao and Friedman BMC Systems Biology  (2016) 10:108 Page 4 of 18
Table 1 The variables of the model; concentration and densities are in units of g/cm3 for cells and g/ml for cytokines
ROS (R): Reactive oxygen species GSK-3 (G): Glycogen synthase kinase-type 3
Aiβ : Amyloid β inside neurons A
o
β : Amyloid β outside neurons
NFT (Fi): Neuronfibrillary tangle inside neurons NFT (Fo): Neuronfibrillary tangle outside neurons
APP (AP): Amyloid precursor protein AβO (AO): Amyloid β oligomer (soluble)
TNF-α (Tα ): Tumor necrosis factor alpha TGF-β (Tβ ): Transforming growth factor beta
IL-10 (I10): Interleukin 10 P: MCP-1
M1: Proinflammatory microglias M2: Anti-inflammatory microglias
MG (MG): Microglias N: Live neurons
A : Astrocytes Nd : Dead neurons
Mˆ1 Peripheral proinflammatory macrophages Mˆ2: Peripheral anti-inflammatory macrophages
τ hyperphosphorylated tau protein H High mobility group box 1 (HMGB1)
hyperphosphorylation of tau. In steady state, the differ-
ence Aiβ −Ai0β is proportional to R. Hence the equation for




⎜⎝λτ0 + λτR︸ ︷︷ ︸
production
−dτ τ︸ ︷︷ ︸
degradation
⎞
⎟⎠ NN0 . (3)
We assume that initially we already have a disease
state. Thus, in particular, the tau proteins are already
hyperphophorylated and ROS induces increases in the
production of these proteins.
Equations for NFT
TheNFTs in neurons (Fi) are formed from the hyperphos-
phorylated tau proteins [4, 6–9], and they are released to
the extraceullar space (and are then labeled F0) when the






















Hyberphosphorated tau proteins, forming neurofibril-
lary tangles, cause microtubles depolymerization and
destruction, resulting in neuron death [4, 6–9]. Neuron
death is also caused by stress from proinflamma-
tory cytokines which is, however, resisted by anti-
inflammatory cytokines [20, 22, 23]. For simplicity we
represent all the proinflammatory cytokines by TNF-α
and all the anti-inflammatory cytokines by IL-10. Hence
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where the death rates of N caused by Fi and Tα are
assumed to depend on their saturation levels.
Equation for astrocytes
Astrocytes are activated primarily by extracellular TNF-α









Equation for dead neurons
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where K¯Nd is a Michaelis-Menten coefficient. The first
two terms on the right-hand side arise from the death of
N cells. The last two terms account for the clearance ofNd
by microglias and peripheral macrophages [48].
Equation for AβO
The AβO are soluble Aβ oligomers and they can diffuse
throughout the brain tissue [49, 50]. Their density AO
satisfies the equation:
∂AO
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where λAO is the rate by which theAO are formed from the
extracellular amyloid β peptides, and DAO	AO accounts
for the diffusion of AO.
Equation for HMGB-1
In general, when cell death occurs through necrosis, dying
cells release HMGB-1 [51]. In AD, HMGB-1 is produced
by dying neurons [52–54]. Hence,
∂H






Activated microglias have two phenotypes: proinflam-
matory M1 and anti-inflammatory M2. They satisfy the
following equations:
∂M1













































where ε1 = TαTα+KTα and ε2 =
I10
I10+KI10 .
Microglias can travel in the brain [55]. Activated
microglias are chemoattracted to dead neurons [10, 13, 15],
more precisely, to the cytokines HMGB-1 produced by
Nd, and this is represented by the second term of the
left-hand side of Eqs. (11), (12). Microglias are acti-
vated by extracelluar NFTs [10, 13, 15], and by soluble
oligomers AO [11, 12]. They become of M1 phenotype
under proinflammatory signals from TNF-α, and of M2
phenotype under anti-inflammatory signals from IL-10.
These facts are expressed by the first term on the right-
hand sides of Eqs. (11), (12); βε1
βε1+ε2 is the ratio by which
the activated microglias become M1 macrophages, and
ε2
βε1+ε2 is the ratio by which activated microglias become
M2 macrophages. The parameter β reflects the ratio
of proinflammatory/anti-inflammatory environment, as
determined by the relative ‘strength’ of Tα v.s. I10.
In addition, there is a transition M1 → M2 under the
TGF-β signaling [32], which is accounted by the second
term on the right-hand side of these equations.
Equations formacrophages
Peripheral macrophages Mˆ are differentiated from mono-
cytes which migrate through the blood vessels. They
satisfy a flux condition
∂Mˆ
∂n + α˜(P)(Mˆ − M0) = 0
on the boundary of the blood vessels, where n is the
outward normal, M0 is the density of the monocytes
in the brain capillaries, and α˜(P) is a function which
depends on the concentration of MCP-1. By averaging
these fluxes from blood vessels, we can represent (as in
[56]) the immigration of Mˆ macrophages into the brain
tissue by a term α˜(P)(M0 − Mˆ). We assume that the
incoming macrophages divide into Mˆ1 and Mˆ2 phenotype
depending on the relative concentrations of TNF-α and
IL-10 [47]. Macrophages Mˆ1 can also change phenotype
to Mˆ2 macrophages under signaling by TGF-β . We finally
note that because of the blood-brain barrier (BBB) we
do not include diffusion of peripheral macrophages, but
we do include chemotaxis by amyloid-β plaques or, more
specifically, by the soluble AO [17–19]. Hence peripheral
macrophages satisfy the following equations:
∂Mˆ1















∂t +∇ · (Mˆ2∇AO)=α(P)(M0 − Mˆ)
ε2












where Mˆ = Mˆ1 + Mˆ2 and α(P) = α PP+KP [56].
Equations for TGF-β , TNF-α MCP-1 and IL-10
Tβ and IL-10 are produced by M2 microglia and Mˆ2
macrophages. TNF-α is produced by proinflammatory
macrophagesM1 and Mˆ1. Hence the equations for Tβ , Tα
and I10 have the following form:
∂Tβ






∂t − DI10	I10 = λI10MM2 + λI10MˆMˆ2︸ ︷︷ ︸
production
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MCP-1 is produced by activated astrocytes [17–19] and
by microglias [12], which are assumed to be ofM2 pheno-
type. Hence
∂P





The estimates of parameters in Eqs. (1)–(18) are given
in “Appendix".
Results and discussions
We simulate the model (1)-(18) in a rectangular domain
 = {(x, y), 0 ≤ x ≤ 1, 0 ≤ y ≤ 1}. We assume that
AO,H,Tβ , I10,Tα and P satisfy periodic boundary conditions.
(19)
We take initial values, for each variable X, to be below
(or above) the expected steady state for X, if X is expected
to grow (or decrease) with the progression of the disease.
A specific choice is given below, but the simulations do
not change, after a short time, with other choices:
Aiβ =10−6 g/ml,Aoβ =10−8 g/ml, τ =1.37×10−10 g/ml, Fi=3.36×10−10 g/ml,
Fo=3.36×10−11 g/ml,N=0.14 g/ml,A=0.14 g/ml,M1=M2=0.02 g/ml,
Mˆ1=Mˆ2=Nd =0 g/ml,H = 1.3×10−11g/ml,Tβ =10−6g/ml,
Tα =2×10−5g/ml, I10=10−5 g/ml,P=5×10−9g/ml.
(20)
We also prescribe the value of ROS in Eqs. (1), (3) by
R = R(t) =
{
R0 t100 0 ≤ t ≤ 100
R0 t > 100
. (21)
Figure 2 shows the average density of all the 18 vari-
ables of the model over a period of 10 years. We first
observe that, for all the species that tend to a steady
state in Fig. 2, the steady states are approximately the
same as those that we assumed in estimating some of
the model parameters. Thus the steady state values of
τ , Fi,H ,M1,M2, Mˆ1, Mˆ2,Tβ ,Tα and I10 are approximately
equal to the values assumed in “Appendix”. We conclude
that estimates of the parameters which were based on
steady state assumptions on macrophages, microglias and
the half-saturation parameters are consistent with the
simulation results.
We next observe that neurons are dying at approx-
imately the rate of 5% a year, which was one of our
important assumptions that was based on clinical data.
We also note that, as the disease progresses, the plaque of
Aβ peptides, Aoβ , and the soluble Aβ oligomers, AO, are
increasing; Aoβ reaches the level of 7×10−6 g/ml, in agree-
ment with clinical data [57], and the assumed average
of AO concentration, KAO , is indeed in good approxima-
tion to the average of the profile of AO in Fig. 2. The
assumed average of the Fo concentration, KFo , is also in
Fig. 2 Average concentration of cytokines and average density of cells. All the parameters are as in Tables 2 and 3
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good agreement with the average of the profile of Fo in
Fig. 2.
We note that Nd nearly stabilizes over time, at the level
assumed in “Appendix," which means that, over time,
macrophages and microglias clear debris of dead cells at
nearly the same rate at which neurons are dying. Hence∣∣∣ ∂Nd∂t
∣∣∣ becomes very small over time, resulting in signifi-
cant decline in extracellular NFT, while intracellular NFTs
(Fi) maintain a comparatively high level.
We finally note that the density of activated astrocytes is
slightly increasing in agreement with a mouse model [58]
which reports that astrocytes become increasingly promi-
nent with the progression of the disease. The increase
in A causes P also to increase, and the average of P is
approximately equal to our estimate of KP in S.I.
Anti-Alzheimer drugs
Until now, all clinical trials aimed to develop drugs that
can cure AD have failed. There are currently no drugs
that can prevent, stop or even delay the progression of
Alzheimer’s disease, and there are many ongoing clinical
trials. According to the 2016 Alzheimer’s Disease Facts
and Figures, and the National Institute of Aging, if no cure
is found, by 2050 the number of alzheimer’s patients in the
U.S. will reach 15 millions and the cost of caring for them
will exceed $ 1 trillion annually.
Avenues for AD therapies include prevention of build
up of plaque (anti-amyloid drugs), preventing tau aggre-
gation, and reducing inflammation. Clinical trials are con-
cerned with both safety and efficacy. Here we shall use our
mathematical model to conduct in silico trials with several
drugs, addressing only the question of efficacy.
Treatment for AD causes changes in the densities of
cells and concentrations of cytokines. In order to deter-
mine the efficacy of a drug, we should observe (i) to what
extend it decreases the death rate of N, since slowing the
death of neurons will improve cognition of patients; and
(ii) to what extend it decreases Aoβ , since Aβ aggrega-
tion mediates rapid dysfunction of synaptic plasticity and
dendritic channels thereby causing memory loss [36–39].
TNF-α inhibitor
Since TNF-α is implicated in generating neurotoxicity
which leads to death of neurons, TNF-α inhibitor (etan-
ercept) has been considered as a drug for Alzheimer’s
patients [59]. In 2015 clinical trials phase 2 [60] the drug
has shown some favorable trends but with “no statistically
significant changes in cognition.” Since there were no seri-
ous adverse events, it was suggested that a larger, broader
group needs to be tested before recommending etanercept
for use for general Alzheimer patients.
We shall apply our model to determine how this TNF-
α inhibitor affects AD patients. We use the following
procedure:
1. Run the model for 300 days in order to ensure that
AD has been diagnosed in patients;
2. Apply continuous treatment by the drug from day
300 until the end of 10 years.
During treatment, the effect of the drug is to replace
Eq. (17) for TNF-α by the equation
∂Tα
∂t − DTα	Tα = λTαM1M1 + λTαMˆ1Mˆ1−dTαTα − fTα ,
(22)
where f is proportional to the amount of etanercept. We
note that since etanercept is a soluble TNF receptor fusion
protein, it stabilizes TNF-α [61] and thus TNF-α is dimin-
ished at rate fTα . The red profiles in Fig. 3 show the
result of the treatment with f = 10dTα , compared to no
treatment.
TGF-β injection
TGF-β is an anti-inflammatory cytokine which induces
phenotype change from proinflammatory to anti-
inflammatory macrophages. It was suggested that TGF-β
mitigates AD pathology [29–34].
We note that the effect of Tβ injection is to decreaseM1
and Mˆ1 (see Eqs. (11), (13)), which results in a decrease
in Tα (by Eq. (17)) and hence in a decrease in neuronal
death rate. To model the treatment by injection of TGF-β
we replace Eq. (15) for Tβ by the equation
∂Tβ
∂t − DTβ 	Tβ = λTβMM2 + λTβMˆMˆ2−dTβTβ + g,
(23)
where g is proportional to the amount of injected TGF-
β . In steady state, Tβ maintains the level of KTβ , while its
degradation rate is dTβ . Hence the source of Tβ in steady
state is dTβTβ . We take g to be 10 times this source, that
is g = 10dTβKTβ . We then follow the same treatment
procedure for TNF-α inhibitor. The light-blue profiles in
Fig. 3 show the results of the treatment, compared to no
treatment.
Anti-Aβ drugs
There are several drugs in Phase 3 clinical trials that aim to
reduce the effect of Aβ aggregation [62]. Among them is
aducanumab, which is thought to be microglia-mediated
phagocytosis and clearance of Aβ [63, 64]. In our model,
this drug will cause a decrease in the concentration of
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Fig. 3 Anti-TNF-α drug (red), etanercept, with f = 10dTα ; TGF-β injection. (light-blue) with g = 10dTβ KTβ . Dark-blue color corresponds to no
treatment, and where several profiles nearly coincide, they are all colored by light-blue. All the other parameters are as in Tables 2 and 3
where h is proportional to the amount of the dozing level;
we take h = 10.
Figure 4 shows the efficacy of several drugs in terms
of N and Aoβ . The lowest curve in Fig. 4a, and the high-
est curve in Fig. 4b, correspond to the case where the
curves of no treatment and several other drugs coincide;
these drugs have negligible efficacy. Following the same
treatment procedure as in the case of TNF-α inhibitor,
Fig. 4 shows no efficacy of aducanumab in terms of N
but significant efficacy in terms of Aoβ in comparison to
no treatment and to treatments by TNF-α inhibitor and
TGF-β injection.
MCP-1 inhibitor
Bindarit was shown to inhibit CCL2 (MCP-1) in brain
tissue [65]. Hence it decreases Mˆ1 (by Eq. (13)), which
results in a decrease in Tα (by Eq. (17)) and thus also
in a decrease in neuronal death rate. Bindarit was also
reported to inhibit Aβ-induced neuronal death in vitro
[66]. Hence it has a therapeutic potential in the treat-
ment of neuroninflammatory/neurodegenerative diseases
like AD [66]. We can conduct in silico trial with bindarit
by revising Eq. (18) for P, replacing it with the equation
∂P
∂t − DP	P = λPAA + λPM2M2−dPP(1 + k) (25)
with k = 10 Following the treatment procedure as in the
case of of TNF-α inhibitor, Fig. 4 shows no efficacy of the
drug in terms ofN and Aoβ in comparison to no treatment.
Methylthiomnium chloride (MTC) is the first identified
tau aggregation inhibitor currently in Phase 3 trial [27]. In
ourmodel the drug will cause a decrease in the production
of tau proteins and in their ability to turn into NFT. We
model this by multiplying the production terms λτ0 and
λτ by 1/10. Following the procedure as in case of TNF-
α inhibitor, we found that the drug has almost negligible
efficacy (not shown here).
Combination therapy
The results of Fig. 4 suggest that a combination ther-
apy with etanercept (TNF-α inhibitor) and aducanumab
(anti-Aβ drug), under the same ’10-fold’ amount, could
both slow the death rate of neurons and decrease the
growth of Aβ in a significant way. Figure 5 shows
the dynamics of N and Aoβ under such combination
of drugs with different proportions of fold numbers:
(etanercept,aducanumab)=(0,0) (no drugs), (10,5), (20,10),
(30,15), (40,20) and (50,25). The reduction in the death of
neurons, after 10 years, compared to the case of no drugs,
is 3.8, 5.2, 6.4, 7.9 and 9.2%, respectively, and the respec-
tive reduction in the concentration of Aβ is 21, 32.2, 43.6,
53.9 and 64.1%.
We next consider combined therapy for any value of
etanercept (f ) and aducanumab (h). We define the N-
efficacy of (f, h), EN (f , h), to be
EN (f , h) = N(f , h) − N(0, 0)N(0, 0) ,
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Fig. 4 Treatment with etanercept (decreasing Tα degradation rate by 10 fold), TGF-β injection (increasing its constitutive source by 10 fold),
aducanumab (increasing the clearance rate of Aoβ by 10 fold), and bindarit (increasing MCP-1 natural degradation by 10 fold). In a, the profiles of no
treatment, bindarit and aducanumab coincide. In b, no treatment and bindarit coincide. The lowest curve in Fig. 4a, and the highest curve in Fig. 4b
, correspond to the case where the curves of no treatment and several other drugs coincide; these drugs have negligible efficacy
where the density N is computed at the end of 10 years.
Similarly we define the anti-Aoβ efficacy by
EAβ (f , h) =
Aoβ(0, 0) − Aoβ(f , h)
Aoβ(0, 0)
where the Aoβ concentration is computed also at the end of
10 years.
Figure 6 is an efficacy map of the combined therapy with
f in range of (0,50) and h in the range of (0,25). For any pair
(f,h) the color columns in Fig. 6a and 6b show the efficacy
for N and anti-Aoβ .
We see that the efficacy of the combined therapy is very
small if f < 20 or h < 10, and it increases sharply with f
and h in the region where {40 < f < 50, 20 < h < 25}.
From Fig. 6 we see that anti-Aβ antibody decreases
the external concentration of Aβ (Aoβ ) with efficacy less
than 0.5 (h=20, f=0). Higher efficacy requires Tα inhibitor
(h=20, f=20) which will protect neuron from death and
prevent astrocytes activation, and thereby reduceAoβ . This
result can be explained by our assumptions in Eq. (2)
where we neglected the production of Aoβ by live neurons
and the increase of Aoβ by ROS.
The PK/PD literature employs the concept of combi-
nation index (φ) in order to assess the level of synergy
between two drugs [67]. This concept was used in sim-
ulations of several diseases (e.g. cancer and microbial
diseases) in order to determine optimal dosage regimens
[67–69]. Since in our AD model it is not clear how to
define φ, and no data are available to evaluate φ, we shall,
instead, introduce the following concept, for example in
the case of etanercept and aducanumab:
We say that these two drugs at concentrations f and g
have positive synergy with respect to N if EN (f , g) >
EN (2f , 0) and EN (f , g) > EN (0, 2g). We accordingly define
the synergy index σN = σN (f , g) by
σN = EN (f , g)/max{EN (2f , 0),EN (0, 2g)}.
Fig. 5 Combined treatment with etanercept fold number f and aducanumab fold number h for several values of (f, h)
































Fig. 6 Efficacy maps. Etanercept (with fold number f ) varies along the
horizontal axis, and aducanumab (with fold number h) varies along
the vertical axis. The column vector indicates the efficacy of treatment
for any pair (f,h): a N-efficacy; b Anti-Aoβ efficacy
Thus, σN > 1 means positive synergy and σN < 1
means negative synergy. The above definition depends on
the doses f, g. If σN is large then the combination therapy
at total amount f + g is much more effective than a single
therapy, at the total same amount, in reducing the death
rate of N. If σN < 1 then a single drug is preferable. Sim-
ilarly one can define the synergy index σAoβ with respect
to Aoβ . Figure 7 shows the synergy index σN for (f, g)
in the range 0 < f < 50 and 0 < g < 25. We see
that there is a positive synergy between etanercept (f ) and
aducanumab (h). Furthermore, given a total amount A of
the combined drugs, so that f+h=A, the synergy increases
as f/g increases. This suggests that in an optimal regimen



















Fig. 7 Synergy map for combination therapy with etanercept (f ) and
aducanumab (h)
The synergy map for σAoβ is similar to that of σN (not
shown here), and so the synergy increases when f/g is
increased.
From Fig. 5 we see that although the amyloid level
are controlled, cell death levels do not decrease signifi-
cantly. This may suggest that other combinations of drugs
may target complimentary pathways more efficiently. For
example, it was suggested in [70] that Amyloid β and tau
combine to induce neuron into cell cycle, which leads to
cell death; accordingly, one could explore using anti-Aβ
and anti tau aggregation in combination therapy.
Sensitivity analysis
Sensitivity analysis on the model parameters can sup-
port the robustness of the simulation results. But it can
also suggest what drugs do not work and what drugs are
more likely to work. We conducted sensitivity analysis on
parameters associated with production and removal rates
of Aoβ , death rates of N, and production rates of TNF-α,
TGF-β and MCP-1:
λN , λA, dNF , dNT , (λTαM1 , λTαMˆ1)γ , (λTβM, λTβMˆ)
× δ, (dAoβM, (λPA, λPM2)ξ , dAoβMˆ),
where we varied λN , λA, dNF , dNT between 12 and twice
their value in Tables 2 and 3, and varied γ , δ, ξ ,  between
1
2 and 2.
Following the sensitivity analysis method described in
[71], we performed Latin hypercube sampling and gener-
ated 2000 samples to calculate the partial rank correlation
coefficients (PRCC) and p-values with respect to the den-
sity of N and with respect to the concentration of Aoβ at
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Table 2 Parameters’ description and value
Parameter Description Value
DAO Diffusion coefficient of AβO 4.32 × 10−2 cm2 day−1 estimated
DH Diffusion coefficient of HMGB-1 8.11 × 10−2 cm2 day−1 estimated
DTα Diffusion coefficient for TNF-α 6.55 × 10−2 cm2 day−1 estimated
DTβ Diffusion coefficient of TGF-β 6.55 × 10−2 cm2 day−1 estimated
DI10 Diffusion coefficient of IL-10 6.04 × 10−2 cm2 day−1 estimated
DP Diffusion coefficient of MCP-1 1.2 × 10−1 cm2 day−1 estimated
λiβ Production rate of A
i
β 9.51 × 10−6 g/ml/day estimated
λN Production rate of Aoβ by neuron 8 × 10−9 g/ml/day estimated
λA Production rate of Aoβ by astrocytes 8 × 10−10 g/ml/day estimated
λτ0 Production rate of tau proteins in health 8.1 × 10−11 g/ml/day estimated
λτ Production rate of tau proteins by ROS 1.35 × 10−11 g/ml estimated
λF Production rate of NFT by tau 1.662 × 10−3/day estimated
λATα Production/activation rate of astrocytes by TNF-α 1.54/day estimated
λAAoβ
Production/activation rate of astrocytes by Aoβ 1.793/day estimated
λAO Production rate of AβO 5 × 10−2/day estimated
λH Production rate of HMGB-1 3 × 10−5/day estimated
λMF Production/activation rate of microglias by NFT 2 × 10−2/day estimated
λMA Production/activation rate of microglias by astrocytes 2.3 × 10−3/day estimated
λM1Tβ Rate ofM1 → M2 6 × 10−3/day estimated
λMˆ1Tβ
Rate of Mˆ1 → Mˆ2 6 × 10−4/day estimated
λTβM Production rate of TGF-β by M 1.5 × 10−2 day−1 [56, 99]
λTβ Mˆ
Production rate of TGF-β by Mˆ 1.5 × 10−2 day−1 [56, 99]
λTαM1 Production rate of TNF-α byM1 3 × 10−2 day−1 estimated
λTα Mˆ1
Production rate of TNF-α by Mˆ1 3 × 10−2 day−1 estimated
λI10M2 Production rate of IL-10 byM2 6.67 × 10−3 day−1 [47, 90]
λI10Mˆ2
Production rate of IL-10 by Mˆ2 6.67 × 10−3 day−1 [47, 90]
λPA Production rate of MCP-1 by astrocytes 6.6 × 10−8 day−1 estimated
λPM2 Production rate of MCP-1 byM2 1.32 × 10−7 day−1 estimated
θ M2/M1 effectivity in clearance of Aoβ 0.9 estimated
α Flux rate of macrophages 5 estimated
β Proinflammatory/anti-inflammatory ratio 10 estimated
γ I10 inhibition ratio 1 estimated
time t=10 years. The results are shown in Fig. 8. All the
p-values were less than 0.01. A positive PRCC (i.e. positive
correlation) for N means that an increase in the param-
eter will increase the number of live neurons. A negative
PRCC for N means that an increase in the parameter will
decrease the number of live neurons. Similarly, a posi-
tive (negative) PRCC for Aoβ means that an increase in the
parameter will increase (decrease) the concentration of
Aoβ . Thus, for example, we see that dNF and dNT are nega-
tively correlated to N and positively correlated to Aoβ . This
is not surprising since, with an increase in dNF and dNT ,
more neurons die (so N decreases) and as a result more
Aβ emerge from the increasingly dying neurons, thus rais-
ing the concentration of Aoβ . The fact that the correlation
coefficients of dNT are significantly larger than the cor-
relation coefficients of dNF , suggests that a drug which
blocks TNF-α would be more effective than a drug which
clears the Fi. The other PRCC values can also be seen to
be consistent with the model dynamics.
We observe that  is negatively correlated to Aoβ . Indeed,
if  is increased, more Aoβ are cleared out (by Eq. (2)). To
see how this affects N we note that if Aoβ is decreased
then AO decreases (by Eq. (9)) and correspondingly
M1 decreases (by Eq. (11)), and then Tα decreases (by
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Table 3 Parameters’ description and value
Parameter Description Value
dAiβ
Degradation rate of Aiβ 9.51/day [82]
dAoβ Degradation rate of A
o
β 9.51/day [82]
dAoβM Clearance rate of A
o
β by microglia 2 × 10−3/day estimated
dAoβ Mˆ
Clearance rate of Aoβ by macrophages 10
−2/day estimated
dτ Degradation rate of tau proteins 0.277/day [88]
dFi Degradation rate of intracellular NFT 2.77 × 10−3/day estimated
dFo Degradation rate of extracellular NFT 2.77 × 10−4/day estimated
dN Death rate of neurons 1.9 × 10−4/day estimated
dNF Death rate of neurons by NFTs 3.4 × 10−4/day estimated
dNT Death rate of neurons by TNF-α 1.7 × 10−4/day estimated
dNdM Clearance rate of dead neurons by M 0.06/day estimated
dNdMˆ Clearance rate of dead neurons by Mˆ 0.02/day estimated
dA Death rate of astrocytes 1.2 × 10−3 day−1 estimated
dM1 Death rate ofM1 microglias 0.015 day
−1 [47, 74]
dM2 Death rate ofM2 microglias 0.015 day
−1 [47, 74]
dMˆ1 Death rate ofM1 macrophages 0.015 day
−1 [47, 74]
dMˆ2 Death rate ofM2 macrophages 0.015 day
−1 [47, 74]
dAO Degradation rate of AβO 0.951/day estimated
dH Degradation rate of HMGB-1 58.71/day [95]
dTα Degradation rate of TNF-α 55.45 day
−1 [47, 74]
dTβ Degradation rate of TGF-β 3.33 × 102 day−1 [56, 99]
dI10 Degradation rate of IL-10 16.64 day
−1 [47]
dP Degradation rate of MCP-1 1.73 day−1[47, 74]
R0 Initial inflammation by ROS 6 estimated
M0 Monocytes concentration in blood 5 × 10−2 estimated
N0 Reference density of neuron 0.14 g/cm3 estimated
M0G Source of microglia 0.047 g/cm
3 estimated
A0 Reference density of astrocytes 0.14 g/cm3 estimated
K¯Aoβ Michaelis-Mention coefficient for A
o
β 7 × 10−3 g/cm3 estimated
K¯Nd Michaelis-Mention coefficient for Nd 10
−3 g/ml estimated
KI10 Half-saturation of IL-10 2.5 × 10−6 g/cm3 estimated
KTβ Half-saturation of TGF-β 2.5 × 10−7 g/ml [90]
KM Half-saturation of microglias 0.047 g/ml estimated
KMˆ Half-saturation of macrophages 0.047 g/ml estimated
KM1 Half-saturation ofM1 microglias 0.03 g/ml estimated
KM2 Half-saturation ofM2 microglias 0.017 g/ml estimated
KMˆ1 Half-saturation of Mˆ1 macrophages 0.04 g/ml estimated
KMˆ2 Half-saturation of Mˆ2 macrophages 0.007 g/ml estimated
KFi Half-saturation of intracellular NFTs 3.36 × 10−10 g/ml [89]
KFo Average of extracellular NFTs 2.58 × 10−11 g/ml estimated
KAO Average of of AβO 1 × 10−7 g/ml estimated
KP Half-saturation of MCP-1 6 × 10−9 g/ml estimated
KTα Half-saturation of TNF-α 4 × 10−5 g/ml estimated
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Fig. 8 The PRCC values of parameter for sensitivity analysis
Eq. (17)); so we may expect N to increase, but perhaps
not much, since we have ignored other indirect inter-
actions from the model. From Fig. 8 we see that  is
indeed positively correlated to N but the correlation is
small. The correlation levels of  with respect to N and Aoβ
suggest that an anti-Aβ drug, like aducanumab, will have
some benefits in reducing Amyloid β , but little benefit in
reducing death of neurons. This is also seen from Fig. 4.
Conclusion
AD is an irreversible progressive neuroninflamma-
tory/neurodegenerative disease that destroysmemory and
cognitive skills. Currently there is no drug that can cure,
stop, or even slow the progression of the disease. Life
expectancy at diagnosis is 10 years, and, at death, 50%
of the brain neurons have already died. AD patients
show abnormal aggregation of beta-amyloids (Aoβ ) and
neurofibrillary tangles (NFTs) of hyperphosphorylated
tau proteins. NFTs destroy microtubles in neurons, which
results in neurons death. Soluble Aoβ oligomers acti-
vate microglias (the resident macrophages in the brain),
thereby initiating inflammatory response. Additionally,
peripheral macrophages, responding to cue from MCP-
1 produced by astrocytes, are attracted to the brain and
increase the inflammatory environment, which is harmful
to neurons.
Figure 1 is a schematic network of AD: it includes
neurons, astrocytes, microglias, peripheral macrophages,
β-amyloids, tau proteins, and several cytokines involved
in the cross-talk among the cells. In the present paper, we
developed a mathematical model of AD based on Fig. 1.
The model can be used to explore the efficacy of drugs
that may slow the progress of the disease. We conducted
several in silico trials with several drugs: etanercept (TNF-
α inhibitor), injection of TGF-β , aducanumab (Anti-Aβ
drug) and bindarit (MCP-1 inhibitor). We found that at
’10-fold’ level, etanercept has the largest efficacy in slow-
ing death of neurons, while aducanumab has the largest
efficacy in reducing the aggregation of Aoβ , although these
efficacies were quite small. Based on these findings we
propose that clinical trials should use a combination ther-
apy with etanercept (f ) and aducanumab (h). In Fig. 6 we
developed efficacymaps for any combination therapy with
0 < f < 50 and 0 < h < 25, and we used this map to
derive, in Fig. 7, a synergy map for σN = σN (f , g). Figure 7
shows that the synergy between f and g increases if f/g
increases, while f+g is kept fixed. This suggests that in an
optimal regimen with fixed total amount, A, of the drugs,
f should be significantly larger than h. We did not con-
sider here, however, adverse side effects that are likely to
limit the amount of drugs that can be given to a patient.
When these limits become better known, one could
then proceed to determine the optimal combination of
etanercept and aducanumab for slowing the progression
of AD.
The mathematical model developed in this paper
depends on some assumptions regarding the mechanism
of interactions involving amyloid, tau and neunofilaments
in AD. There are currently not enough data to sort out
competing assumptions. Hence the conclusion of the
paper regarding combination therapy should be taken
with caution.
Our mathematical model focused on the progression of
AD in terms of neurons death and amyloid β aggregation.
But dendritic pathologies also play an important role in
the disease. Dendritic abnormalities in AD include dys-
trophic neuritides, reduction in dendritic complexity and
loss in dendritic spines [36, 37]. In particular, Aβ plaques
affect dendritic channels, and NFTmediates synaptic dys-
function [36–39]. Recent studies also begin to address




In the sequel, in an expression of the form XX+KX in the
context of activation, the half-saturation parameter KX is
taken to be the steady state of the species X provided X
tends to a steady state. Hence in a steady state equation
this factor is equal to 12 . If X does not tend to a steady
state then the parameter KX will be taken to be the esti-
mated average of X over a period of 10 years, the average
survival time of AD patients [73]. In an expression of the
form 11+γX/KX (where γ = γ (X)) in the context of inhibi-
tion, KX is again the half-saturation of X, so that in steady
state the inhibition is 1/(1 + γ ). If cells Y phagocytose
species X, then the clearing rate is proportional to Y XX+K¯X
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where the Michaelis-Menten constant K¯X depends only
on the ‘eating capacity’ of Y, so K¯X has no relation to the
half-saturation of X.
Diffusion coefficients
The diffusion coefficient of proteins (Y ) are propor-
tional to 1/M1/3Y , where MY is the molecular weight [74].






where MV and DV are the molecular weight and the dif-
fusion coefficient of VEGF. Since DV = 8.64 × 10−2 cm2
day−1[76],MV = 24 kDa [76],MP = 8.9 kDa [77],MTβ =
55 kDa [78],MTα = 55 kDa [79],MI10 = 70 kDa [46], and
MH = 29 kDa [80], we get DP = 1.20 × 10−1 cm2day−1,
DTβ = 6.55 × 10−2 cm2day−1, DTα = 6.55 × 10−2
cm2day−1, DI10 = 6.04 × 10−2 cm2day−1 and DH =
8.11 × 10−2 cm2day−1.
Molecular weight of Aβ is 24 kDa [81], so in solu-
ble state its diffusion coefficient would be 8.64 × 10−2
cm2day−1. We assume that soluble oligomer AβO has a
smaller diffusion coefficient, namely, DAO = 4.32 × 10−2
cm2day−1.
Eq. (1)
By [82], the half-life of Aiβ is 1.5–2 h in mice. Hence dAiβ =
dAoβ = ln21.75 × 24=9.51 /day. Membrane proteins APP shed
amyloid β , some end up inside the cell and some outside
the cell. We assume that in healthy steady state Aiβ = Aoβ ,
however the simulation results do not change apprecia-
bly if we take Aoβ > Aiβ . According to [57], the density
in brain-gray matter of Aoβ is approximately 1000 ng/g in
control and 7000 ng/g in AD. Hence, from the steady state
of Eq. (1) in a healthy normal case, Aiβ = 10−6 g/ml and
λiβ = dAiβ × 10−6=9.51 × 10−6 g/ml/day. From the steady
state of Eq. (1) in AD and Eq. (21) we then get that R0 = 6.
The brain has 75% water and 60% of its dry matter is
fat. We assume that the average density of brain tissue
is 1 g/cm3. The human brain has 100 billion neurons,
and its weight is approximately 1400 g, so its volume is
approximately 1400 ml. Hence its neurons number den-
sity is 7×107 neurons/cm3. The diameter of neurons is 16
μm [83]. Accordingly, we estimate the volume of 1 neu-
ron to be 2 × 10−9 cm3, and the neurons density is then
7 × 107 × 2 × 10−9 g/cm3, that is N0 = 0.14 g/cm3.
Eq. (2)
The number of neurons is three times the number of
microglia [55], hence KMˆ = 13N0 = 0.047 g/ml.
By [16] an astrocyte produces much less Aβ than a
neuron, so we take λA = 110λN .
Microglias are the first responders to NFTs and AβO.
Peripheral macrophages arrive later, and their immune
response may perhaps exceed that of microglia, but this
is currently not known [12, 84]. We assume that in
steady state the microglias density M and the peripheral
macrophages density Mˆ are equal, so that Mˆ = KMˆ =
M = KM = 0.047 g/ml. Motivated by the inflam-
matory immune attack in AD [85], we assume that, in
steady state, the proinflammatory macrophages exceed
the anti-inflammatory macrophages, and that proinflam-
matory peripheral macrophages exceed the proinflamma-
torymicroglias. Thus, in steady state, Mˆ1 > Mˆ2,M1 > M2
and Mˆ1 > M1, and we take KMˆ1 = 0.04, KMˆ2 = 0.007,
KM1 = 0.03, KM2 = 0.017.
Activated microglias are poorly phagocytic for Aβ com-




Taking dAoβMˆ = 10
−2/day, we then have
dAoβM = 2 × 10−3/day.
We assume that Mˆ1 andM1 are more effective than Mˆ2
andM2 in clearing Aβ , and take θ = 0.9.
We assume that survival time of patients with AD is 10
years, and that at the end-stage 50% of their neurons have
died [73]. Hence, the death rate of N is dN = ln210 years =
1.9 × 10−4/day.
By [57], Aoβ = 7 × 10−6 g/ml. We assume that the
clearance of Aoβ by macrophages and microglias is nearly
unlimited (i.e., it is almost linear in Aoβ ) by taking K¯Aoβ =
103Aoβ = 7× 10−3 g/ml. To estimate λN , we first consider













To estimate the average of
∣∣ ∂N
∂t
∣∣, we use the equation









∣∣ for 500 < t < 1000 days vary very
little, i.e., from 1.8×10−5 g/ml/day to 1.9×10−5 g/ml/day.
We take
∣∣∣dNdt
∣∣∣ = 1.8×10−5 g/ml/day as the average of
∣∣∣dNdt
∣∣∣
over 10 years, but other choices do not affect significantly
our simulation results. We then get that λN = 4 × 10−9
g/ml/day.
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The estimate of λN was based on the steady-state
assumption in Eq. (2). However, in AD the Aβ peptides are
continuously aggregating, so that the steady state assump-
tion needs to be revised.We do this by increasing the value
of λN : we take λN = 2× 4× 10−9=8× 10−9 g/ml/day, and
then λA = 8 × 10−10 g/ml/day.
The number of astrocytes is approximately equal to the
number of neurons [86, 87], hence A0 = N0 = 0.14 g/ml.
Eq. (3)
Half-life of tau proteins is 60 hours [88]. Hence dτ =
ln2
60/24 = 24ln2=0.277/day. Concentration of tau proteins is
in healthy normal individuals is 137 pg/ml and, in AD, 490
pg/ml [89]. From the steady state of Eq. (3) in the healthy
case, we have λτ0 = dτ τ , where τ = 137 pg/ml. Hence
λτ0=3.78 × 10−11 g/ml/day. Similarly, λτ0 + λτR = dτ τ
in AD, where τ = 490 pg/ml. Hence we have λτR =
8.1 × 10−11 g/ml, or λτ = 1.35 × 10−11/day.
Eqs. (4) and (5)
We assume that neurofibrillary tangles inside neurons are
much more stable than tau proteins, taking dFi = 1102 dτ =
2.77 × 10−3/day. We also assume that extracellular NFTs
do not degrade as fast as internalized NFTs, taking dFo =1
10dFi = 2.77 × 10−4/day.
We also assume that 60% of the hyperphosphorglated
tau proteins become neurofibrillary tangles. From the
steady state of Eq. (4) we then have that λF = 0.6dFo .
Hence λF = 1.662 × 10−3/day.
Eq. (6)
It is not known whether the rate of death of neurons
caused by NFT is larger or smaller than the death rate
caused by Tα . We take dNF = 2dNT , but the simulation
of the model in the case where dNT = 2dNF are very sim-
ilar (not shown here). Assuming that at steady state of
Eq. (6) the concentrations of Fi, Tα and I10 are at half-
saturation, we get dNF
(
1
2 + 14 11+γ
)
= dN , so that dNF =
4+4γ
3+2γ ×1.9×10−4/day and dNT = 2+2γ3+2γ ×1.9×10−4/day. In
particular, if γ = 1 then dNF = 2.4× 10−4/day and dNT =
1.7 × 10−4/day. We take KI10 = 2 × 10−6 g/cm3 (which is
somewhat larger than the estimated half-saturation of I10
in lung inflammation [47, 90]).We assume that in AD, 60%
of hyperphosphorylated tau proteins (whose concentra-
tion in disease is 490 pg/ml [89]) are in NFT form, so that
KFi = 0.6×490 pg/ml=2.94×10−10 g/ml. In [89] the con-
centration of tau protein was taken uniformly in the tissue
of patients. We assume, however, that the concentration
of NFT is higher inside neurons than outside neurons,
and take KFi = 3.36 × 10−10 g/ml, KFo = 2.58 × 10−11
g/ml. From the steady state of Eq. (17) and the estimates
of λTαM1 and λTαMˆ1 (see under Eq. (17) below) we get
Tα = 4 × 10−5 g/ml, so that KTα = 4 × 10−5 g/ml.
Eq. (7)
We take the half-life of astrocytes to be the same as the
half-life of ganglionic glial cells, that is, 600 days [91].
Hence dA = 1.2 × 10−3/day. We assume that the activa-
tion of astrocytes is due more to TNF-α than to Aβ , and
take λATαTα = 2λAAoβAoβ . By the steady state of Eq. (7) we
then get λATα = 1.4/day, and λAAoβ = 1.63/day. Actually, in
a mouse model of AD, the number of activated astrocytes
is increasing [58]. So we compensate for this by increasing
both λATα and λAAoβ by a factor 1.1, taking λATα = 1.54/day
and λAAoβ = 1.793/day.
Eq. (8)
In mice experiments [92], macrophages phagocytosed
apoptotic cells at rates that varied in the range 0.1–1.27/h.
We assume that necrotic cells (and their debris) in human
brain are phagocytosed by peripheral macrophages at rate
dNdMˆ = 0.2/day. We also assume that microglia play agreater role in clearing necrotic neurons, and take dNdM =
3 × 0.2=0.6/day. We also take K¯Nd = 10−3 g/ml.
Eq. (9)
We assume the degradation rate of AO is much slower
than that of Aoβ , taking dAO = 110dAoβ = 0.951/day. The
ratio of soluble AO to total Aoβ is approximately 125 [93].
From the steady state of Eq. (9) we then get λAO =1
25dAO = 3.8 × 10−2/day.
The estimate of λAO was based on the steady-state
assumption in Eq. (9). However, in AD the soluble
Aβ oligomer is continuously increasing, following the
increase in Aoβ , so the steady-state assumption needs to be
revised. We do this by increasing the above value of λAO,
taking the new value to be λAO = 5 × 10−2/day.
Eq. (10)
Concentration of HMGB-1 in neurons is 1.3 ng/ml [94],
hence H = 0.14 × 1.3 ng/ml=1.8 × 10−10 g/ml. Half-life
of HMGB-1 is 17 minutes [95], so that dH = 58.71/day.
We assume thatNd stabilizes somewhere below 2.5×10−4
g/ml. From the steady state of Eq. (10), we then get λH =
3 × 10−5/day.
Eqs. (11) and (12)
We take dM1 = dM2 = 0.015/day [47, 90]. Then, our
assumption (under Eq. (2)) that KM1 > KM2 suggests that
β > 1. We take β = 10.
We take M0G = KM = 0.047 g/ml and α = 5. In
the absence of data, we take the production rate λMF of
macrophages by NFT to be the same as the production
rate under stimulation byM. Tuberculosis in [90], namely,
λMF = 2 × 10−2/day. We assume that production rate of
macrophages by NFT is larger than the production rate by
AO, and take λMA = 2.3 × 10−3/day.
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By [57] the concentration of Aβ in AD is 7 × 10−6 g/ml
and, by [55], the ratio of AO to Aoβ is 125 , so that KAO =
1
25 × 7 × 10−6 = 2.8 × 10−7 g/ml.
We assume that more NFT reside within neurons than
outside them, so thatKFo is smaller thanKFi . Recalling that
KFi = 3.36×10−10 g/ml, we takeKFO = 2.58×10−11 g/ml.
The coefficient λM1Tβ is the rate by which TGF-β affects
the change of phenotype from M1 to M2. In the case of
infection in the lung by M. tuberculosis, under inflamma-
tory conditions caused by the pathogen, λM1Tβ = 6 ×
10−3/day [90]; we take it to be the same in the present case.
We take KTβ = 2.5 × 10−7 g/ml, and KI10 = 2.5 × 10−6
g/ml.
Eqs. (13) and (14)
Peripheral macrophages immigrate into the brain of AD
[96, 97]. We assume that, because of the BBB, the con-
centration of monocytes in the brain capillaries must be
significantly higher than the concentration of peripheral
macrophages already in the tissue. Recalling that in steady
state Mˆ = 0.047 g/ml, we take M0 = 0.05 g/ml. The
parameter α was estimated by 5, in order to make the
asymptotic behavior of Mˆ in the simulations agree with its
assumed steady state of 0.047 g/ml (under Eq. (2)). When
microglia cells are activated, they become either of M1 or
M2 phenotype. But peripheral macrophages are initially
biased toward Mˆ1 phenotype rather than Mˆ2 phenotype,
since KTα > KI10 . We assume, in line with this bias toward
Mˆ1, that the transition rate from Mˆ1 into Mˆ2 phenotype
by TGF-β is at a smaller rate than the corresponding tran-
sition rate for microglias, that is, λMˆ1Tβ < λM1Tβ . We take
λMˆ1Tβ = 6 × 10−4/day.
Eq. (17)
Activated alveolar macrophages produce TNF-α at rate
4.86 × 10−3/day [47]. We assume that proinflammatory
macrophages produce TNF-α at a larger rate (five fold),
taking λTαM1 = λTαMˆ1 = 3 × 10−2 g/ml.
Eq. (18)
Astrocytes secrete MCP-1 [17–19] but activated anti-
inflammatory microglias also secrete MCP-1. We assume
that the production rate by astrocytes in larger than that
by M2, and take λPA = 12λPM2 . MCP-1 concentration in




2A0 + λPM2M2 = dPP,
with P = 6 × 10−9 g/ml and dP = 1.73/day [74], we get
λPM2 = 1.2 × 10−7/day and λPA = 6 × 10−8/day [47].
SinceA is increasing in time, also P is increasing in time.
Hence the steady state assumption needs to be revised.We
do it by increasing λPA and λPM2 by a factor 1.1, taking
λPM2 = 1.32 × 10−7/day, and λPA = 6.6 × 10−8/day.
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